Polymerase Chain Reaction (PCR) Global Market - Forecast To 2027

Publishing Date : August, 2021
Report Code : HCBT 0099
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

PCR is an enzymatic reaction process in which multiple copies of desired DNA sequence is obtained in a short period of time. The technique is broadly accepted in research and clinical diagnostic application due to its high accuracy and sensitivity. The evolution of PCR instruments with different designs such as interchangeable modules, dual & multiblock capacity, development of advanced Real-time PCR and digital PCR with multiplexing and analytical capabilities, development of various reagents & consumables and incorporation of microfluidic and other advanced technologies for the development of portable PCR will further advance the PCR applications in clinical diagnostic and industrial applications.

The Polymerase Chain Reaction (PCR) global market is estimated to be $21,408.8 million in 2020. The factors driving the market are raising the incidence of infectious and non-infectious diseases, increase in demand for early disease detection, diagnosis & treatment, growing focus towards the development of personalized medicine, increasing advancements in PCR technologies and increasing demand for point of care testing. However, lack of skilled personnel to use advanced PCR Instruments and data analysis software, high cost of advanced instruments, presence of alternative molecular and immunology techniques, and stringent government regulations are expected to hamper the market growth.

The PCR market is classified into products, application, end-user and geography. The PCR products global market is segmented into instruments, reagents & consumables and software & services. Among the products, the Reagents & consumables segment accounted for the largest revenue in 2020 due to an increase in demand for reagents & consumables for research and diagnostic applications. Reagents and consumables are sub-segmented into enzymes, dNTPs, template DNA, primers and probes, buffers, reagents kits or master mixes and assay kits, nuclease free water, consumable and others (dye and beads). Among these Reagents kits or master mixes and assay kits is accounted for the highest revenue in 2020 due to an increase in demand for assay kits in diagnostic applications particularly in COVID-19 diagnosis. The enzymes are fastest growing consumable segment at a high single digit CAGR from 2020 to 2027. The PCR instruments global market is sub-segmented into Standard PCR, Real-Time PCR and Digital PCR. Among the instruments, Real-Time PCR is accounted for the highest revenue in 2020 due to increased utilization of real-time PCR instruments in diagnostic applications particularly in COVID-19 diagnosis and research applications. The digital PCR is fastest growing instruments segment at a mid teen CAGR from 2020 to 2027. The software & Services market is accounted for revenue of $xx million in 2020.

The application market is segmented into clinical diagnostics, industrial applications, and others (blood screening and HLA typing). Among the applications, Clinical diagnostics is accounted for the highest revenue in 2020 due to an increase in demand for PCR-based diagnostic solutions. Industrial applications is fastest growing segment at a mid single digit CAGR from 2020 to 2027. The Clinical diagnostic market is sub-segmented into infectious diseases and non-infectious diseases. Among these, infectious diseases are accounted for the highest revenue in 2020 due to an increase in the incidence of infectious diseases, particularly in COVID-19. Non-infectious diseases is fastest growing segment at a double digit CAGR from 2020 to 2027. Infectious diseases are further segmented into Hepatitis B and C testing, Tuberculosis diagnosis, HIV diagnosis, COVID-19 diagnosis and other infectious diseases. Among these, COVID-19 diagnosis is accounted for the highest revenue in 2020 due to an increase in the incidence of COVID-19 and an increase in demand for PCR-based early diagnosis solutions. Hepatitis B and C testing is fastest growing segment at a low single digit CAGR from 2020 to 2027. Non-infectious diseases market is sub-segmented into Cancer, Genetic Testing and Others. Among these, the Cancer segment accounted for the highest revenue in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027 due to the increase incidence and prevalence of cancer and increasing demand for early disease diagnosis solutions. The genetic testing is fastest growing segment at a low teen CAGR from 2020 to 2027. The industrial application market is further classified into Agriculture, Environment, Applied Testing, Animal Husbandry, Biomedical Research and Others. Among these, Biomedical Research is accounted for the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027.  The applied testing is fastest growing segment at a mid single digit CAGR from 2020 to 2027. The Biomedical Research market is further sub-segmented into DNA sequencing, Genotyping, Gene Expression Analysis, DNA cloning and others. Among these, DNA sequencing is accounted for the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. Genotyping is fastest growing segment at a mid single digit CAGR from 2020 to 2027. Applied testing is further segmented into forensics and food safety testing. Among them, Forensics is accounted for the highest revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. Food safety testing is fastest growing segment high single digit CAGR from 2020 to 2027.

The end- user market is segmented into Hospitals and laboratories, Pharmaceuticals, CRO's and Biotech companies, Academics and Research institutions and others. Among these, Hospitals and laboratories accounted for the largest revenue in 2020 due to an increase in demand for PCR-based early diagnosis tastings. Academics and Research institutions is fastest growing segment at a mid single digit CAGR from 2020 to 2027.

By geography, the PCR global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K. and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and the Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). North America accounted for the largest revenue in 2020. The factors such as increasing R&D and health care expenditure, increase in the incidence of infectious diseases particularly COVID-19 and non-infectious diseases with increased demand for early detection, diagnosis & treatment, increasing funding from the government for the disease research, development of diagnostic and therapeutic solutions, growing focus towards personalized medicine and a growing number of startup companies engaged in developing advanced digital PCR systems & portable PCR solutions to use in research & diagnostics are driving the market. 

The PCR global market is competitive and all the players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the PCR global market include Abbott Laboratories, Inc. (U.S.), F.Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands) and Thermo Fisher Scientific, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • U.K.
  • France
  • Rest of Europe
  • Asia-Pacific 
  • China
  • Japan
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Africa
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.5     PRIMARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     Rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment
        • 3.3.1.2     Increasing focus towards the development of personalized medicines
        • 3.3.1.3     Growing demand for point of care testing
        • 3.3.1.4     Increasing demand for prenatal testing
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     Lack of skilled personnel to use advanced instruments
        • 3.3.2.2     High cost of advanced PCR system
        • 3.3.2.3     Development of alternate technologies
        • 3.3.2.4     Stringent regulatory framework limits advancements in the PCR market
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     INDIA
      • 3.4.5     JAPAN
    • 3.5     PORTER’S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     BARGAINING POWER OF SUPPLIERS
      • 3.5.4     BARGAINING POWER OF BUYERS
      • 3.5.5     COMPETITIVE RIVALRY
    • 3.6     SUPPLY CHAIN ANALYSIS
    • 3.7     FUNDING SCENARIO
    • 3.8     PATENT ANALYSIS
    • 3.9     TECHNOLOGICAL ADVANCEMENTS
      • 3.9.1     INTRODUCTION
      • 3.9.2     CRYSTAL DIGITAL PCR TECHNOLOGY
      • 3.9.3     REAL TIME REMOTE MONITORING
      • 3.9.4     ARTIFICIAL INTELLIGENCE IN PCR
      • 3.9.5     INFRARED MEDIATED NON-CONTACT THERMOCYCLING
      • 3.9.6     NANO-PCR
    • 3.10     IMPACT OF COVID-19 ON PCR MARKET
    • 3.11     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.11.1     PCR GLOBAL MARKET SHARE ANALYSIS
      • 3.11.2     STANDARD PCR GLOBAL MARKET SHARE ANALYSIS
      • 3.11.3     REAL TIME PCR GLOBAL MARKET SHARE ANALYSIS
      • 3.11.4     DIGITAL PCR GLOBAL MARKET SHARE ANALYSIS
  • 4     PCR GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     INSTRUMENTS
      • 4.2.1     STANDARD PCR
      • 4.2.2     REAL TIME PCR
      • 4.2.3     DIGITAL PCR
    • 4.3     REAGENTS AND CONSUMABLES
      • 4.3.1     ENZYMES
      • 4.3.2     DEOXYNUCLEOTIDE TRIPHOSPHATE'S (dNTP'S)
      • 4.3.3     TEMPLATES OR CONTROLS
      • 4.3.4     PRIMERS AND PROBES
      • 4.3.5     BUFFERS
      • 4.3.6     REAGENT KITS OR MASTER MIXES AND ASSAY KITS
      • 4.3.7     NUCLEASE FREE WATER
      • 4.3.8     CONSUMABLES
      • 4.3.9     OTHER REAGENTS AND CONSUMABLES
    • 4.4     SOFTWARE & SERVICES
  • 5     PCR GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     CLINICAL DIAGNOSTICS
      • 5.2.1     INFECTIOUS DISEASES
        • 5.2.1.1     Hepatitis B and C testing
        • 5.2.1.2     Tuberculosis diagnosis
        • 5.2.1.3     HIV Diagnosis
        • 5.2.1.4     COVID-19 Diagnosis
        • 5.2.1.5     Others
      • 5.2.2     NON-INFECTIOUS DISEASES
        • 5.2.2.1     Cancer
        • 5.2.2.2     Genetic testing
        • 5.2.2.3     Others
    • 5.3     INDUSTRIAL APPLICATIONS
      • 5.3.1     AGRICULTURE
      • 5.3.2     ENVIRONMENT
      • 5.3.3     APPLIED TESTING
        • 5.3.3.1     Forensics
        • 5.3.3.2     Food safety testing
      • 5.3.4     ANIMAL HUSBANDRY
      • 5.3.5     BIOMEDICAL RESEARCH
        • 5.3.5.1     DNA Sequencing
        • 5.3.5.2     Genotyping
        • 5.3.5.3     Gene expression analysis
        • 5.3.5.4     DNA Cloning
        • 5.3.5.5     Others
      • 5.3.6     OTHER PCR INDUSTRY APPLICATIONS
    • 5.4     OTHER PCR APPLICATIONS
  • 6     PCR GLOBAL MARKET, BY END-USERS
    • 6.1     INTRODUCTION
    • 6.2     HOSPITALS AND LABORATORIES
    • 6.3     PHARMACEUTICALS, CRO'S AND BIOTECH
    • 6.4     ACADEMICS AND RESEARCH INSTITUTIONS
    • 6.5     OTHERS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     U.K.
      • 7.3.3     FRANCE
      • 7.3.4     REST OF EUROPE
    • 7.4     ASIA-PACIFIC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATIN AMERICA
      • 7.5.3     MIDDLE EAST & AFRICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     APPROVALS
    • 8.3     NEW PRODUCT LAUNCH
    • 8.4     COLLABORATIONS AND PARTNERSHIPS
    • 8.5     ACQUISITIONS
    • 8.6     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES, INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     BECTON DICKINSON AND COMPANY
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIOMERIEUX SA
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENSTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     BIO-RAD LABORATORIES
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     DANAHER CORPORATION
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     EXACT SCIENCES CORPORATION
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     F.HOFFMANN-LA ROCHE LTD
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MERCK KGAA
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     PERKINELMER, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     QIAGEN N.V.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     THERMO FISHER SCIENTIFIC, INC.
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     PCR GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 3     INSTRUMENTS GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 4     INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 5     STANDARD PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 6     REAL TIME PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 7     DIGITAL PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 8     REAGENTS & CONSUMABLES GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 9     REAGENTS AND CONSUMABLES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 10     ENZYMES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 11     DNTP'S GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 12     TEMPLATES OR CONTROLS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 13     PRIMERS AND PROBES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 14     BUFFERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 15     REAGENT KITS OR MASTER MIXES AND ASSAY KITS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 16     NUCLEASE FREE WATER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 17     CONSUMABLES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     OTHER REAGENTS AND CONSUMABLES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 19     SOFTWARE & SERVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 20     PCR GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 21     CLINICAL DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2020-2027) ($MN)
      • TABLE 22     CLINICAL DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 23     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY DISEASE TYPE, (2019-2027) ($MN)
      • TABLE 24     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 25     HEPATITIS B AND C TESTING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     TUBERCULOSIS DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 27     HIV DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 28     COVID-19 DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 29     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 30     NON-INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 31     NON-INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 32     CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 33     GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 35     INDUSTRIAL APPLICATIONS GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 36     INDUSTRIAL APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 37     AGRICULTURE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 38     ENVIRONMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 39     APPLIED TESTING GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 40     APPLIED TESTING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 41     FORENSICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 42     FOOD SAFETY TESTING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 43     ANIMAL HUSBANDRY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 44     BIOMEDICAL RESEARCH GLOBAL MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 45     BIOMEDICAL RESEARCH GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 46     DNA SEQUENCING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 47     GENOTYPING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 48     GENE EXPRESSION ANALYSIS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 49     DNA CLONING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 50     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 51     OTHER PCR INDUSTRY APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 52     OTHER PCR APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 53     PCR GLOBAL MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 54     HOSPITALS AND LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 55     PHARMACEUTICALS, CRO'S AND BIOTECH GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 56     ACADEMICS AND RESEARCH INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 57     OTHERS MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 58     PCR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 59     NORTH AMERICA PCR MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 60     NORTH AMERICA INSTRUMENTS MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 61     NORTH AMERICA REAGENTS & CONSUMABLES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 62     NORTH AMERICA PCR MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 63     NORTH AMERICA CLINICAL DIAGNOSTICS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 64     NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE, BY DISEASE TYPE, (2019-2027) ($MN)
      • TABLE 65     NORTH AMERICA NON-INFECTIOUS DISEASES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 66     NORTH AMERICA INDUSTRIAL APPLICATIONS MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 67     NORTH AMERICA APPLIED TESTING MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 68     NORTH AMERICA BIOMEDICAL RESEARCH MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 69     NORTH AMERICA PCR MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 70     NORTH AMERICA PCR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 71     EUROPE PCR MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 72     EUROPE INSTRUMENTS MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 73     EUROPE REAGENTS & CONSUMABLES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 74     EUROPE PCR MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 75     EUROPE CLINICAL DIAGNOSTICS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 76     EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY DISEASE TYPE, (2019-2027) ($MN)
      • TABLE 77     EUROPE NON-INFECTIOUS DISEASES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 78     EUROPE INDUSTRIAL APPLICATIONS MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 79     EUROPE APPLIED TESTING MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 80     EUROPE BIOMEDICAL RESEARCH MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 81     EUROPE PCR MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 82     EUROPE PCR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 83     ASIA-PACIFIC PCR MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 84     ASIA-PACIFIC INSTRUMENTS MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 85     ASIA-PACIFIC REAGENTS & CONSUMABLES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 86     ASIA-PACIFIC PCR MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 87     ASIA-PACIFIC CLINICAL DIAGNOSTICS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 88     ASIA-PACIFIC INFECTIOUS DISEASES MARKET REVENUE, BY DISEASE TYPE, (2019-2027) ($MN)
      • TABLE 89     ASIA-PACIFIC NON-INFECTIOUS DISEASES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 90     ASIA-PACIFIC INDUSTRIAL APPLICATIONS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 91     ASIA-PACIFIC APPLIED TESTING MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 92     ASIA-PACIFIC BIOMEDICAL RESEARCH MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 93     ASIA-PACIFIC PCR MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 94     ASIA-PACIFIC PCR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 95     ROW PCR MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 96     ROW INSTRUMENTS MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 97     ROW REAGENTS & CONSUMABLES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 98     ROW PCR MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 99     ROW CLINICAL DIAGNOSTICS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 100     ROW INFECTIOUS DISEASES MARKET REVENUE, BY DISEASE TYPE, (2019-2027) ($MN)
      • TABLE 101     ROW NON-INFECTIOUS DISEASES MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 102     ROW INDUSTRIAL APPLICATIONS MARKET REVENUE, BY APPLICATION TYPE, (2019-2027) ($MN)
      • TABLE 103     ROW APPLIED TESTING MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 104     ROW BIOMEDICAL RESEARCH MARKET REVENUE, BY TYPE, (2019-2027) ($MN)
      • TABLE 105     ROW PCR MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 106     ROW PCR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 107     APPROVALS (2020-2021*)
      • TABLE 108     NEW PRODUCT LAUNCH (2020-2021*)
      • TABLE 109     COLLABORATIONS AND PARTNERSHIPS (2020-2021*)
      • TABLE 110     ACQUISITIONS (2020-2021*)
      • TABLE 111     OTHERS (2020-2021*)
      • TABLE 112     ABBOTT LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 113     ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 114     ABBOTT LABORATORIES, INC.: DIAGNOSTICS REVENUE, BY SUB-SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 115     ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 116     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 117     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q2) ($MN)
      • TABLE 118     BECTON DICKINSON AND COMPANY: LIFE SCIENCES REVENUE, BY SUB-SEGMENTS, (2019-2021) (Q2) ($MN)
      • TABLE 119     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 120     BIOMERIEUX: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 121     BIOMEURIEX: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 122     BIOMEURIEX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 123     BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 124     BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 125     BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 126     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q1) ($MN)
      • TABLE 127     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2019-2021)(Q1) ($MN)
      • TABLE 128     DANAHER CORPORATION: TOTAL REVENUE, BY REGION, (2019-2021) (Q1) ($MN)
      • TABLE 129     EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 130     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q1) ($MN)
      • TABLE 131     EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1)($MN)
      • TABLE 132     F.HOFFMANN-LA RACHE: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 133     F.HOFFMANN-LA ROCHE: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 134     F.HOFFMANN-LA ROCHE: DIAGNOSTICS REVENUE, BY SEGMENTS (2019-2021) (Q1) ($MN)
      • TABLE 135     F.HOFFMAN LA ROCHE: DIAGNOSTICS REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 136     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2019-2020) (Q1) ($MN)
      • TABLE 137     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 138     MERCK KGAA COMPANY: TOTAL REVENUE, BY LIFE-SCIENCE SUB-SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 139     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 140     PERKINELMER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 141     PERKINELMER, INC.: TOTAL REVENUE BY SEGMENT, (2019-2021) (Q1) ($MN)
      • TABLE 142     PERKINELMER, INC.: TOTAL REVENUE, BY REGION, (2019-2021) (Q1) ($MN)
      • TABLE 143     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021)(Q1) ($MN)
      • TABLE 144     QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 145     QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 146     THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 147     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2019-2021) (Q1) ($MN)
      • TABLE 148     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)

      LIST OF FIGURES

      • FIGURE 1     PCR GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: PCR GLOBAL MARKET
      • FIGURE 3     PCR GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     PCR GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     PCR GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     PCR GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     PCR GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     PCR GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     PCR MARKET: PATENT FILING BY MAJOR PLAYERS(2017-2021*)
      • FIGURE 11     PCR GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 12     STANDARD PCR GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 13     REAL TIME PCR GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 14     DIGITAL GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 15     PCR GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 16     INSTRUMENTS GLOBAL MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 17     TYPES OF INSTRUMENTS BASED ON SAMPLE HOLDING CAPACITY, PORTABILITY AND MECHANISM OF OPERATION
      • FIGURE 18     REAGENTS AND CONSUMABLES GLOBAL MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 19     REAGENTS AND CONSUMABLES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 20     ENZYMES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 21     DNTP'S GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 22     TEMPLATES OR CONTROLS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 23     PRIMERS AND PROBES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 24     BUFFERS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 25     REAGENT KITS OR MASTER MIXES AND ASSAY KITS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 26     CONSUMABLES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 27     OTHER REAGENTS AND CONSUMABLES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 28     PCR GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 29     CLINICAL DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATTION TYPE (2020 V/S 2027) (%)
      • FIGURE 30     CLINICAL DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 31     INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 32     INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 33     HIV DIAGNOSIS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 34     COVID-19 DIAGNOSIS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 35     NON-INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 36     NON-INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027 (%)
      • FIGURE 37     GENETIC TESTING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027 (%)
      • FIGURE 38     OTHERS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027 (%)
      • FIGURE 39     INDUSTRIAL APPLICATIONS GLOBAL MARKET SHARE, BY APPLICATION TYPE, BIOMEDICAL RESEAECH AND APPLIED TESTING GLOBAL MARKET SHARE, BY TYPE (2020) (%)
      • FIGURE 40     INDUSTRIAL APPLICATIONS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 41     ENVIRONMENT GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 42     APPLIED TESTING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 43     FORENSICS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 44     BIOMEDICAL RESEARCH GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 45     DNA SEQUENCING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 46     GENOTYPING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 47     PCR GLOBAL MARKET SHARE, BY END-USERS (2020 V/S 2027) (%)
      • FIGURE 48     PHARMACEUTICALS, CRO’S AND BIOTECH GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 49     ACADEMICS AND RESEARCH INSTITUTIONS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 50     PCR GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN),
      • FIGURE 51     PCR GLOBAL MARKET REVENUE, BY GEOGRAPHY (2020) ($ MN)
      • FIGURE 52     NORTH AMERICA PCR MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 53     NORTH AMERICA INSTRUMENT MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 54     NORTH AMERICA REAGENTS AND CONSUMABLES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 55     NORTH AMERICA PCR MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
      • FIGURE 56     NORTH AMERICA CLINICAL DIAGNOSTICS MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 57     NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 58     NORTH AMERICA NON-INFECTIOUS DISEASES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 59     NORTH AMERICA INDUSTRIAL APPLICATIONS MARKER SHARE BY APPLICATION TYPE, BIOMEDICAL RESERCH, APPLIED TESTING MARKET SHARE, BY TYPE (2020) (%)
      • FIGURE 60     NORTH AMERICA PCR MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 61     NORTH AMERICA PCR MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 62     U.S. PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 63     REST OF NORTH AMERICA PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 64     EUROPE PCR MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 65     EUROPE INSTRUMENT MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 66     EUROPE REAGENTS AND CONSUMABLES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 67     EUROPE PCR MARKET SHARE, BY APPLICATIONS (2020 V/S 2027) (%)
      • FIGURE 68     EUROPE CLINICAL DIAGNOSTICS MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 69     EUROPE INFECTIOUS DISEASES PCR MARKET SHARE, BY DISEASE TYPE (2020 V/S 2027) (%)
      • FIGURE 70     EUROPE NON-INFECTIOUS DISEASES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 71     EUROPE INDUSTRIAL APPLICATIONS MARKET SHARE, BY APPLICATION TYPE, BIOMEDICAL RESEARCH AND APPLIED TESTING MARKET SHARE, BY TYPE (2020) (%)
      • FIGURE 72     EUROPE PCR MARKET SHARE, BY END-USERS (2020 V/S 2027) (%)
      • FIGURE 73     EUROPE PCR MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 74     GERMANY PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 75     U.K. PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 76     FRANCE PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 77     REST OF EUROPE PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 78     ASIA-PACIFIC PCR MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
      • FIGURE 79     ASIA-PACIFIC INSTRUMENTS MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 80     ASIA-PACIFIC REAGENTS AND CONSUMABLES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 81     ASIA-PACIFIC PCR MARKET SHARE, BY APPLICATIONS (2020 V/S 2027) (%)
      • FIGURE 82     ASIA-PACIFIC CLINICAL DIAGNOSTIC MARKET SHARE, BY APPLICATION TYPE (2020 V/S 2027) (%)
      • FIGURE 83     ASIA-PACIFIC INFECTIOUS DISEASES MARKET SHARE, BY DISEASE TYPE (2020 V/S 2027) (%)
      • FIGURE 84     ASIA-PACIFIC NON-INFECTIOUS DISEASES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 85     ASIA-PACIFIC INDUSTRIAL APPLICATIONS MARKET SHARE, BY, APPLICATION TYPE, BIOMEDICAL RESEARCH AND APPLIED TESTING MARKET SHARE, BY TYPE (2020) (%)
      • FIGURE 86     ASIA-PACIFIC PCR MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 87     ASIA-PACIFIC PCR MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 88     JAPAN PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 89     CHINA PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 90     INDIA PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 91     REST OF APAC PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 92     ROW PCR MARKET SHARE, BY PRODUCTS (2020 V/S 2027) (%)
      • FIGURE 93     ROW INSTRUMENTS MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 94     ROW REAGENTS AND CONSUMABLES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 95     ROW PCR MARKET SHARE, APPLICATIONS (2020 V/S 2027) (%)
      • FIGURE 96     ROW CLINICAL DIAGNOSTICS MARKET SHARE, BY APPLICAION TYPE (2020 V/S 2027) (%)
      • FIGURE 97     ROW INFECTIOUS DISEASES MARKET SHARE, BY DISEASE TYPE (2020 V/S 2027) (%)
      • FIGURE 98     ROW NON-INFECTIOUS DISEASES MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 99     ROW INDUSTRIAL APPLICATIONS MARKET SHARE, BY APPLICATION TYPE, BIOMEDICAL RESEARCH AND APPLIED TESTING MARKET SHARE TYPE (2020) (%)
      • FIGURE 100     ROW PCR MARKET SHARE, BY END-USER (2020 V/S 2027) (%)
      • FIGURE 101     ROW PCR MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
      • FIGURE 102     BRAZIL PCR MARKET REVENUE, BY PRODUCTS, APPLICATION AND END-USERS (2020 VS 2027) ($MN)
      • FIGURE 103     REST OF LATIN AMERICA PCR MARKET REVENUE, BY PRODUCTS, APPLICATION AND END-USERS (2020 VS 2027) ($MN)
      • FIGURE 104     MIDDLE EAST & AFRICA PCR MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USER (2020 V/S 2027) ($MN)
      • FIGURE 105     KEY GROWTH STRATEGIES, (2020-2021*)
      • FIGURE 106     SWOT: ABBOTT LABORATORIES, INC.
      • FIGURE 107     SWOT: BECTON DICKINSON AND COMPANY
      • FIGURE 108     SWOT: BIOMERIEUX
      • FIGURE 109     SWOT: BIO-RAD LABORATORIES
      • FIGURE 110     SWOT: DANAHER CORPORATION
      • FIGURE 111     SWOT: EXACT SCIENCES CORPORATION
      • FIGURE 112     SWOT: F. HOFFMANN-LA ROCHE LTD.
      • FIGURE 113     SWOT: MERCK KGAA
      • FIGURE 114     SWOT: PERKINELMER, INC
      • FIGURE 115     SWOT: QIAGEN N.V.
      • FIGURE 116     SWOT: THERMO FISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     3B BlackBio Biotech India Limited
      • 2     3CR Bioscience
      • 3     Abbott Laboratories, Inc.
      • 4     ACTGene, Inc.
      • 5     ADS Biotec, Inc.
      • 6     Agilent Technologies
      • 7     Ahram Biosystems, Inc.
      • 8     Altona Diagnostics GmbH
      • 9     Amoy Diagnostics
      • 10     Ampliqon A/S
      • 11     Analytik Jena AG
      • 12     Anatolia Geneworks
      • 13     Andiatec GmbH
      • 14     AniCon Labor GmbH
      • 15     Anitoa Systems, LLC
      • 16     Atila Bio Systems Inc
      • 17     Becton Dickinson and Company
      • 18     BforCure
      • 19     BGI Group
      • 20     Binx Health Inc.
      • 21     Bio Basic Inc.
      • 22     BioCheck, Inc.
      • 23     Biofidelity
      • 24     BioinGentech ,
      • 25     BIOLABMIX LLC
      • 26     Biomeme, Inc
      • 27     Biomerieux SA
      • 28     Bioneer Corporation
      • 29     Bio-Rad Laboratories, Inc.
      • 30     Bioron GmbH
      • 31     Biosynex S.A.
      • 32     Biotecon Diagnostics GmbH
      • 33     Biotype Diagnostic GmbH
      • 34     Blue-Ray Biotech
      • 35     Brooks Life Sciences
      • 36     Bruker
      • 37     CareDx, Inc.
      • 38     Carpegen GmbH
      • 39     Chai Inc.
      • 40     Cleaver Scientific Ltd.
      • 41     CLONIT Srl.
      • 42     Co-Diagnostics
      • 43     Combinati INC
      • 44     Convergent-technologies
      • 45     Corning, Inc.
      • 46     CyberGene AB
      • 47     Da An Gene Co.
      • 48     Danaher Corporation
      • 49     Devyser AB
      • 50     DiaCarta, Inc.
      • 51     DiaSorin S.p.A.
      • 52     Dropworks, Inc.
      • 53     Entopsis, Inc.
      • 54     EntroGen
      • 55     Eppendorf, AG
      • 56     Eurofins Scientific S.E.
      • 57     Exact sciences
      • 58     F.Hoffmann-La Roche AG
      • 59     Fluidigm corporation
      • 60     Genedrive plc
      • 61     GeneFirst Ltd.
      • 62     Genekam Biotechnology AG
      • 63     GeneProof A.S.
      • 64     Genesystem.co.kr
      • 65     Genome Diagnostics B.V.
      • 66     Genome Diagnostics Pvt Ltd.
      • 67     Genomed
      • 68     Genomictree Inc.
      • 69     GNA Biosolutions GmbH
      • 70     Hangzhou LongGene Scientific Instruments Co.,Ltd
      • 71     Hologics
      • 72     Hy Laboratories Ltd.
      • 73     Hygiena, LLC
      • 74     INTAS Science Imaging Instruments GmbH
      • 75     Invivoscribe, Inc
      • 76     Jena Bioscience GmbH
      • 77     JN Medsys
      • 78     Kaneka Eurogentec S.A.
      • 79     Kogene.co.kr
      • 80     KOMA Biotech, Inc.
      • 81     Kyratec
      • 82     LABGENE Scientific SA
      • 83     Macrogen Inc.
      • 84     Menarini Diagnostics
      • 85     Merck KgaA
      • 86     Meridian Bioscience
      • 87     MicroGEM
      • 88     Minerva Biolabs GmbH
      • 89     miniPCR bio
      • 90     Minute Molecular Diagnostics
      • 91     Molbio Diagnostics Pvt. Ltd.
      • 92     Molzym GmbH & Co. KG
      • 93     Mylab Discovery Solutions
      • 94     Nimagen B.V.
      • 95     Norgen Biotech Corp.
      • 96     Novacyt
      • 97     Nuclein, LLC.
      • 98     Ocimum Biosolutions, Ltd
      • 99     Pathofinder B.V.
      • 100     PCR Biosystems Ltd
      • 101     PCR Max Ltd.
      • 102     PentaBase ApS
      • 103     Perkin Elmer
      • 104     Precipio, Inc.
      • 105     Premier Biosoft International
      • 106     Promega Corporation
      • 107     Qiagen N.V.
      • 108     Qualiplante SAS
      • 109     QuantuMDx
      • 110     Quidel Corporation
      • 111     Reagecon Diagnostics Ltd.
      • 112     Scope Fluidics
      • 113     Seegene, Inc.
      • 114     Siemens Healthcare GmbH
      • 115     Sinaclon
      • 116     SolGent co, LTD
      • 117     SpeeDx
      • 118     Star Array company
      • 119     Stilla Technologies
      • 120     Takara Bio Inc.
      • 121     Tetracore, Inc.
      • 122     Thermo Fisher Scientific, Inc.
      • 123     Ubiquitome
      • 124     Vircell S.L.
      • 125     Visby Medical
      • 126     Zhengzhou Nanbei Instrument Equipment Co. Ltd.
      • 127     Zymo Research Corporation